Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13592112 | 0.98 | ALDH1A1 (0.34) | ALDH1A1HRH3TDP1CA12CA1 | |
| SCHEMBL24090272 | 0.98 | ALDH1A1 (0.34) | ALDH1A1HRH3TDP1CA12CA1 | |
| SCHEMBL25877714 | 0.86 | HRH3 (0.39) | ALDH1A1HRH3TDP1CA12CA1 | |
| SCHEMBL18503245 | 0.83 | LMNA (0.48) | HRH3 | |
| SCHEMBL18503149 | 0.82 | HRH3 (0.37) | HRH3 | |
| SCHEMBL18419063 | 0.82 | HRH3 (0.37) | HRH3 | |
| SCHEMBL7739899 | 0.81 | ALDH1A1 (0.39) | ALDH1A1TDP1CA12CA1CA2 | |
| SCHEMBL27570999 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TDP1CA12CA1CA2 | |
| SCHEMBL133695 | 0.81 | HRH3 (0.41) | HRH3TDP1 | |
| SCHEMBL42956 | 0.81 | ALDH1A1 (0.48) | ALDH1A1TDP1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGNERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20180155332-A1 | SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT | YALE UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20170281784-A1 | PROTEIN-PROTEIN INTERACTION INDUCING TECHNOLOGY | ARVINAS OPERATIONS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160089446-A1 | Modified Hydrogels | ASCENDIS PHARMA A/S (DK) | 2016-03-31 | — | — | US | disclosed |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | ASCENDIS PHARMA INC. | 2015-10-22 | — | — | US | disclosed |
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-7378448-B2 | Diphenylether amide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378448-B2 | Diphenylether amide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070287751-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | ALDH1A1 1468/4885HRH3 3565/4885TDP1 426/4885 |
| US-20170281784-A1 | PROTEIN-PROTEIN INTERACTION INDUCING TECHNOLOGY | HSPBP1, PEBP1, PMAIP1 | ALDH1A1 4813/4885HRH3 3358/4885TDP1 2795/4885 |
| US-20160089446-A1 | Modified Hydrogels | CD44, DNPH1, PHYKPL | ALDH1A1 229/4885HRH3 1514/4885TDP1 598/4885 |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | OPRM1, OPRD1, OPRK1 | ALDH1A1 837/4885HRH3 174/4885TDP1 4648/4885 |
| US-20070112036-A1 | Opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | ALDH1A1 2092/4885HRH3 512/4885TDP1 4460/4885 |
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | MAPT, PSEN1, PSEN2 | ALDH1A1 3938/4885HRH3 2989/4885TDP1 379/4885 |
| US-20180155332-A1 | SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT | PLAUR, C5AR1, C3AR1 | ALDH1A1 3982/4885HRH3 1027/4885TDP1 4245/4885 |
| US-20070287751-A1 | Opioid Receptor Antagonists | OPRK1, OPRM1, OPRD1 | ALDH1A1 2190/4885HRH3 469/4885TDP1 4417/4885 |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | ALDH1A1 2047/4885HRH3 439/4885TDP1 3984/4885 |
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | GAS6, HIF1AN, TMEM41B | ALDH1A1 4237/4885HRH3 3775/4885TDP1 3587/4885 |
| US-20070179129-A1 | Opioid receptor antagonists | OPRK1, OPRM1, OPRL1 | ALDH1A1 1658/4885HRH3 711/4885TDP1 4289/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | ALDH1A1 1481/4885HRH3 933/4885TDP1 3766/4885 |
| US-20070010558-A1 | Opioid receptor antagonists | OPRM1, OPRK1, OPRL1 | ALDH1A1 2100/4885HRH3 669/4885TDP1 4428/4885 |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | VEGFA, KDR, FLT1 | ALDH1A1 805/4885HRH3 1739/4885TDP1 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.